Digital mental health absorbed substantial capital between 2020 and 2022 and is now consolidating around operators that can contract with payers and large employers at scale. Cerebral's regulatory exposure on prescribing reset the bar for clinical oversight, and Ginger's absorption into Headspace signalled platform consolidation. Funds still leading rounds prioritise therapist utilisation, contracted revenue and clinical model durability over DTC subscriber growth.

The active investor mix here is narrower than it looks. Healthcare-focused funds with named behavioural health practices - General Catalyst Health, 7wireVentures, Define Ventures, Oxeon, F-Prime - lead most payer- and employer-contracted rounds; consumer health investors and the funds that backed the early DTC wave still cover the subscription side; and the payer and benefits CVCs - Optum Ventures, CVS Health Ventures, BlueCross BlueShield Venture Partners - engage where in-network contracting is real. Flow has direct relationships across this set and runs outreach against funds with a current lead in the matching distribution model.

Flow has experience running VC fundraising processes for digital mental health companies across DTC therapy and coaching platforms, employer and EAP mental health programmes, payer-contracted therapy and psychiatry networks and condition-specific operators in anxiety, depression, substance use and child and adolescent care. Our extensive investor network spans early-stage seed funds, growth-stage investors, and strategic and corporate VC arms.